Effectiveness of Acupuncture, Mind and Body Practices, and Natural Products for Insomnia: an overview of systematic reviews

Jin Ju Yeo¹, Jang Won Lee¹,², Kyung Sik Kim³, Min Kyung Hyun²*

¹Department of Preventive Medicine, Dongguk University Graduate School of Korean Medicine, Seoul, Republic of Korea
²Department of Preventive Medicine, College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea
³Department of Korean Medicine, College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea

Received May 13, 2022
Reviewed June 2, 2022
Accepted August 2, 2022

Objectives: This overview summarizes the evidence for the effectiveness and safety of complementary therapies for insomnia through systematic reviews (SRs) and meta-analyses (MAs).

Methods: A comprehensive literature search on SRs and MAs for complementary therapies for insomnia was conducted using six databases.

Results: This overview included 30 SRs/MAs. The Pittsburgh Sleep Quality Index (PSQI) analysis of insomnia included 383 randomized controlled trials and 31,748 participants. Twenty-four SRs/MAs (80%) out of 30 SRs/MAs reported a positive result, and six SRs/MAs reported a partially positive result. The most frequently used form of acupuncture reported a positive effect in 89.5% (17/19) of SRs/MAs and a superior effect to western medicine, sham/placebo, and no treatment. The lack of protocol registration and the excluded studies list resulted in generally poor methodological and reporting quality in SRs/MAs with AMSTAR 2.

Conclusion: This overview confirmed that complementary therapies positively affected the PSQI scores in patients with insomnia. However, better-designed primary studies are needed to strengthen the relevant evidence in the future. A more stringent assessment of multiple systematic reviews 2 must be followed when performing SR and MA.

Keywords: complementary therapy, insomnia, overview, systematic review

INTRODUCTION

Insomnia is a sleep-wake disorder in which one (or more) chief complaints of dissatisfaction with sleep quantity or quality, such as difficulty initiating sleep, difficulty maintaining sleep characterized by frequent waking or problems returning to sleep after waking, and early-morning waking with an inability to return to sleep [1]. Sleep takes up to 20%-40% of the day and is one of the most important biological requirements for maintaining human health and high quality of life [2]. Insufficient sleep leads to short-term effects, such as loss of concentration and attention, poor quality of life, decreased productivity, and accidents in everyday life. Long-term effects include increased morbidity and mortality from hypertension, diabetes, stroke, and mental diseases [3].

Approximately one-third of adults report insomnia symptoms, and in primary care settings, approximately 10%-20% of individuals complain of significant insomnia disorders [1]. The prevalence of insomnia is steadily increasing among adults yearly [4-6]. Although conventional behavioral and pharmaceutical treatments for insomnia can be effective, many people seek alternative therapies to improve sleep [7]. According to a survey, 45% of adults with insomnia reported using at least one complementary and alternative medicine (CAM) [8].

The CAMs frequently used for insomnia symptoms include acupuncture, moxibustion, tai chi, yoga, Tui Na, and herbal
Overview SR for Complementary Therapy for Insomnia

Overview SR for Complementary Therapy for Insomnia

www.journal-jop.org

www.journal-jop.org

medicine. CAM for insomnia is increasingly popular among doctors and patients [9]. Many research reports on insomnia and CAM are available, but most have reported results focused on randomized controlled trials (RCTs) or one or two CAMs [10, 11].

Overview studies on CAM for insomnia based on meta-analyses (MAs) and systematic reviews (SRs) are rare. This overview reviewed the SR with or without MA of complementary therapies in patients with insomnia disorder to identify the current evidence level and suggest future research and practice.

MATERIALS AND METHODS

1. Protocol and registration

The review protocol was registered on the Research Registry (Review Registry Unique Identifying Number: reviewregistry1059).

2. Research question

This study aimed to determine the status, effectiveness, safety, and methodological quality of SRs and MAs publications on complementary therapy for insomnia. The PICO can be described as follows:

1) Type of participant
Participants diagnosed with insomnia clinically or according to national or international standards by health care providers or researchers were included. The gender, age, race, nationality, time of illness, comorbidities, etc., were not restricted.

2) Types of interventions
All complementary therapies, including acupuncture, mind and body practices (MBP), and natural products.

3) Types of outcome measurements
Primary outcome: The Pittsburgh Sleep Quality Index (PSQI) evaluated the sleep quality of people with insomnia [12].

Secondary outcomes: Seven outcomes, including the insomnia severity index (ISI) [13], the Athens insomnia scale (AIS) [14], the sleep onset latency (SOL), the total sleep time (TST), the wake time after sleep onset (WASO), the number of awakenings (NOA), and the sleep efficiency (SE).

4) Type of study design
SR with or without MA on RCTs.

3. Search strategy

This overview searched the following databases with language restrictions for English and Korean: PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, KoreaMed (www.koreamed.org), KMbase (kmbase.medric.or.kr), and ScienceON (https://scienceon.kisti.re.kr) from their inception to November 2020. The search strategies were applied to each database using MeSH terms and natural language associated with the keywords “sleep disorders,” “insomnia,” and “complementary therapies” (Supplementary Table S1).

4. Data selection and extraction

Following the search, three reviewers (Yeo, Lee, and Kim) independently checked the titles and abstracts of the included articles to select potential eligible articles. The full texts of the chosen articles were screened according to the inclusion and exclusion criteria. Three independent reviewers performed data extraction. All discrepancies were resolved by consensus or consultation with a fourth reviewer. The data extraction form consisted of the authors’ name, year of publication, country of authors’ affiliation, participant characteristics, interventions, comparator, funding source, outcomes, results, and adverse events.

The main and subgroup results from each MA were extracted for the MA results. The SR results were classified and extracted according to whether the included RCT was statistically improved after extracting each SR/MA. If the results for each outcome measurement were all positive effects, the SR/MA was classified as P; a partially positive effect was classified as partially positive (pP); all negative effects were classified as N; a classification of U was given when positive and negative effects were mixed, or there was no difference.

5. Methodological quality assessment

The quality assessment was conducted by three reviewers independently based on the “assessment of multiple systematic reviews 2” (AMSTAR2), a 16-item validated measurement tool for assessing the methodological quality of SR [15]. The AM-
STAR2 items were evaluated as “Yes,” “Partial Yes,” and “No.” The overall confidence of the review results was rated as high, moderate, low, and critically low based on the number of critical or noncritical flaws [15].

**RESULTS**

1. Search result

A total of 28,125 records were retrieved using the search strategy. Of the remaining 160 SR/MAs after deduplication and primary eligibility selection, 30 (25 in SR and MA and 5 in SR) were finally selected (Fig. 1). The following reasons led to the exclusion of the 130 SRs/MAs: patients without insomnia (n = 43), not complementary therapy (n = 28), no major outcomes to extract (n = 24), not SR (n = 23), not SR for RCT (n = 11), and not written in English or Korean (n = 1) (Supplementary Table S2).

![Figure 1. Study selection process.](image)

### Table 1. Outcomes of the included SRs/MAs according to the intervention

| Interventions        | SR and MA PSQI | ISI | AIS | SOL | TST | WASO | NOA | SE | SR PSQI | ISI | AIS | SOL | TST | WASO | NOA | SE |
|----------------------|----------------|-----|-----|-----|-----|------|-----|----|--------|-----|-----|-----|-----|------|-----|----|
| Acupuncture          | 16             | 4   | 5   | 4   | 5   | 3    | 1   | 5  | 3*     | 2   | 2   | NR  | NR  | NR   | NR  | 2* |
| MBP                  | 4              | 2   | NR  | 1   | 2   | 1    | NR  | 2  | 1      | 2   | 1   | 1   | 1   | 1    | 1   | NR |
| Natural products     | 5              | NR  | 2   | 4   | 5   | 1    | NR  | 3  | 1      | 1*  | NR  | 1*  | 1*  | NR   | 1*  | 1* |
| Total                | 25             | 6   | 7   | 9   | 12  | 5    | 1   | 10 | 5      | 3   | 3   | 2   | 2   | 1    | 1   | 3  |

Note: *One SR reported multiple outcomes (PSQI, ISI, SOL, TST, SE) using acupuncture, MBP, and natural product interventions. Abbreviations: PSQI, Pittsburgh Sleep Quality Index; ISI, Insomnia Severity Index; AIS, Athens Insomnia Scale; SOL, sleep onset latency; TST, total sleep time; WASO, wake after sleep onset; NOA, number of awakenings; SE, sleep efficiency; NR, non-reported; MBP, mind and body practices; MA, meta-analysis; SR, systematic review.
| 1st author (year) | No. of participants | No. of included RCT | Sample sizes per RCT | Mean age (range) | % of female | Comorbid disease | Funding source (Y/N/NR) |
|-------------------|---------------------|---------------------|----------------------|------------------|-------------|------------------|------------------------|
| Cao (2009) [25]   | 3811                | 10                  | 22-181               | NR (13-85)       | NR          | Poststroke (220), depression (179), schizophrenia (60), cervical spondylosis (166), drug addiction (100), end-stage renal disease (204) | Y                      |
| Cheuk (2012) [26] | 2293                | 33                  | 22-200               | NR (15-98)       | NR          | Stroke, end-stage renal disease, perimenopause, pregnancy, psychiatric diseases | Y                      |
| Yeung (2012) [27] | 4115                | 40                  | 13-785               | NR               | NR          |                  | Y                      |
| Lan (2015) [28]   | 1429                | 15                  | 21-300               | NR (18-78)       | 64.30%      |                  | Y                      |
| Ni (2015) [29]    | 7886                | 76                  | 42-366               | 28-74.1 (15-84)  | 56.70%      |                  | Y                      |
| Lee (2016) [30]   | 1111                | 13                  | 30-300               | NR               | NR          | Stroke           | Y                      |
| Shergis (2016) [31]| 2289                | 26                  | 33-180               | NR (17-75)       | 56.20%      |                  | Y                      |
| Choi (2017) [21]  | 475                 | 6                   | 45-120               | NR (41-76)       | NR          | Cancer           | Y                      |
| Dong (2017) [24]  | 1678                | 18                  | 45-187               | NR (18-75)       | 54.10%      | Depression       | Y                      |
| Huang (2017) [16] | 4140                | 57                  | 18-198               | NR               | NR          |                  | Y                      |
| Rubio-Arias (2017) [32] | 660          | 5                   | 30-249               | 48.6-55.8 (NR)   | 100%        | Postmenopausal women | N                      |
| Cao (2019) [33]   | 5533                | 73                  | 22-196               | NR (18-60)       | NR          |                  | Y                      |
| Feng (2019) [19]  | 1999                | 22                  | 30-150               | NR (NR)          | 55%         |                  | Y                      |
| Liu (2019) [20]   | 946                 | 9                   | 12-271               | NR               | NR          | Chronic pain     | Y                      |
| Wang (2019) [34]  | 4506                | 49                  | 26-410               | NA (21-78.1)     | NR          |                  | Y                      |
| Zhang (2019) [35] | 1500                | 15                  | 33-227               | 29-44.85 (NR)    | NR          |                  | Y                      |
| Zhao (2019) [18]  | 928                 | 14                  | 40-155               | NR (18-95)       | NR          | Hypertension, diabetes, post-stroke, cerebral stroke, acute cerebral infarction, hepatocirrhosis, maintenance hemodialysis, chronic obstructive pulmonary disease, and hip fracture | Y                      |
Table 2. Continued

| 1st author (year) | No. of participants | No. of included RCT | Sample sizes per RCT | Mean age (range) | % of female | Comorbid disease | Funding source (Y/N/NR) |
|-------------------|---------------------|---------------------|---------------------|------------------|------------|------------------|-----------------------|
| Birling (2020)    | 1780                | 19                  | 60-150              | 34.7-68.1 (> 18) | 54%        | Schizophrenia (1), hypertension (1), people with insomnia with a specific Chinese medicine pattern (1) | N                     |
| Kim (2019)        | 1521                | 19                  | 50-382              | NR (> 18)        | NR         |                  |                       |
| Li (2020)         | 1549                | 14                  | 47-198              | NR               | 63.40%     |                  |                       |
| Liu (2020)        | 1061                | 13                  | 57-203              | NR (17-67)       | NR         | Perimenopausal women (1), depression (3), anxiety (1) | Y                     |
| Wang (2020)       | 2029                | 22                  | 57-268              | 35.38-66.8 (NR)  | 59.90%     |                  | Y                     |
| Wang (2020)       | 520                 | 5                   | 30-216              | NR               | 66.50%     |                  | Y                     |
| Zhang (2020)      | 1108                | 15                  | 27-192              | 36.6-58.55 (NR)  | NR         |                  | Y                     |
| Zhao (2020)       | 1685                | 18                  | 50-298              | NR               | NR         | Hypertension     | Y                     |
| SR                |                      |                     |                     |                  |            |                  |                       |
| Yeung (2009)      | 1956                | 20                  | 30-190              | NR (13-76)       | NR         |                  | NR                    |
| Sarris (2011)     | 1806                | 20                  | 30-405              | NR               | NR         |                  | Y                     |
| Xie (2013)        | 1376                | 12                  | 60-330              | 30.6-62 (NR)     | 57.20%     |                  | NR                    |
| Wang (2017)       | 436                 | 4                   | 40-200              | NR               | NR         | Coronary heart disease: or need long-term care facilities (suffered from cerebral vascular accidents, dementia, chronic psychiatric conditions or psychosis, chronic obstructive pulmonary disease, or central nervous system injury); or anxiety | N                     |
| Lowe (2019)       | 609                 | 11                  | 23-123              | 44-80 (30-90)    | 70.20%     |                  | N                     |

Abbreviations: MA, meta-analysis; SR, systematic review; Y, Yes; N, No; NR, non-reported; PTSD, posttraumatic stress disorder symptoms.
2. Publication trend

An analysis of the publishing trend for the included SRs/MAs based on the first author’s information showed that the authors came from five countries, including China (73.3%), Australia (10%), the Republic of Korea (10%), Spain (3.3%), and the United Kingdom (3.3%). The annual publishing trend was 50% (15/30) in 2019 and 2020, with > 73.3% (22/30) being published since 2016 (Supplementary Table S3).

The most frequently reported interventions were acupuncture (63.3%, 19/30), followed by natural products (20%, 6/30) (Supplementary Table S4).

Nine articles (8 MAs, 1 SR) [16-24] were reported with only PSQI (primary outcome), and the rest were reported with PSQI and secondary outcomes (ISI, AIS, SOL, TST, WASO, NOA, and SE) (Table 1).

3. Characteristics of included SRs/MAs

Table 2 [16-45] lists the main characteristics of the included MAs/SRs. Thirty SRs/MAs reported the PSQI outcomes for insomnia. Among them, MA included 25 studies, and SR in-
included five [23, 42-45].

The total number of participants was 62,735 [436-7, 886], the number of included RCTs was 673, and the sample size of each RCT ranged from 12-785.

Age was reported in 21 SRs/MAs (70%), and five SRs/MAs included adolescents.

The age range of the participants was 13-98 years.

Gender was reported in 12 SRs/MAs (40%), and in all SRs/MAs where gender was mentioned, > 50% were female, and in one case were only female.

Eighteen SRs/MAs did not report the comorbidity of insomnia; six SRs/MAs reported single comorbidity, and six SRs/MAs reported multiple comorbidities. The comorbidities reported were cancer, depression, postmenopausal women, stroke, and posttraumatic stress disorder (Table 2). Twenty-eight SRs/MAs (93.3%) reported the presence or absence of funding (Table 2).

4. Methodological and reporting quality of the included SRs/MAs

AMSTAR-2 was used to evaluate the methodological quality of the included SRs/MAs. Although the SR/MA quality was generally low, half of the SRs/MAs were published before the development of AMSTAR-2 in September 2017 and were evaluated retrospectively. Twenty SRs/MAs [17-20, 23, 24, 27-32, 34-37, 40-42, 45] were evaluated as critically low methodological quality; the main reasons were an omission in the protocol registration and the excluded studies list. Nine SRs/MAs (30%, 9/30) provided a review method in advance of the protocol, and three SRs/MAs (10%, 3/30) provided a list of the excluded studies. Additionally, two SRs/MAs (6.7%, 2/30) reported the funding sources for the research in the review analysis. Among the AMSTAR2 items, however, > 90% of SRs/MAs were reported well in Q1, Q3, Q6, Q9, Q13, Q14, and Q16 (Fig. 2, Supplementary Table S5).

5. Effects of included SRs/MAs

1) Primary outcome: Global score on PSQI

PSQI is a self-assessment questionnaire that assesses sleep quality and disturbances over one month [12].

In 30 MAs/SRs, 383 RCTs (31,748 participants) were included in the PSQI analysis of insomnia. Of the 30 SRs/MAs, 24 SRs/MAs (80%, 21 MAs and 3 SRs) reported a positive effect (P), and six SRs/MAs reported a pP (Table 3 [16-45], Supplementary Tables S6, 7).

(1) Acupuncture

The acupuncture reported in the SRs/MAs was manual acupressure, auricular, electroacupuncture, needle-rolling, and warm acupuncture. Among 30 SRs/MAs, 19 SRs/MAs reported the effects of acupuncture on the PSQI based on insomnia. Of these, 17 SRs/MAs (89.5%, 17/19) reported positive results. The remaining two SRs/MAs reported partially positive results [24, 43]. As a result, acupuncture was reported to be effective for insomnia except for some SRs/MAs using electroacupuncture and needle-rolling acupuncture.

① Acupuncture vs. western medicines

In 13 out of 19 SRs/MAs [16-18, 20-22, 24, 25, 30, 31, 33, 42, 43], PSQI was reported by comparing the effects of acupuncture to western medicines for insomnia. Twelve out of 13 SRs/MAs reported that acupuncture was more effective than western medicine, and one SR/MA [43] reported that acupuncture (needle-rolling acupuncture) and clonazepam had the same effect.

② Acupuncture vs. sham/placebo acupuncture

In 13 out of 19 SRs/MAs [16, 20, 24-28, 31, 33, 38, 41, 43, 44], PSQI was reported by comparing the effect of acupuncture to sham/placebo acupuncture for insomnia. Among 13 SRs/MAs, 11 SRs/MAs reported that acupuncture was more effective than sham/placebo acupuncture, and two SRs/MAs [24, 43] reported similar effects between electroacupuncture and sham/placebo acupuncture.

③ Acupuncture vs. no treatment

Three out of 19 SRs/MAs [25, 26, 33] compared acupuncture with no treatment for insomnia, and all reported that acupuncture was effective.

(2) MBP

Five out of 30 SRs/MAs [19, 32, 34, 40, 45] reported the effect of MBP on PSQI for insomnia. Three SRs/MAs [32, 34, 40] reported positive effects, and two SRs/MAs [19, 45] reported partially positive results.

① Tui na

One SR/MA reported the PSQI results of Tui Na therapy in insomnia [19]. Tui Na therapy was superior to estazolam therapy in the treatment areas (head and abdomen). Still, there was no significant difference between Tui Na therapy and estazolam therapy in the treatment areas (head and trunk, head, trunk, and extremities).

② Exercise

PSQI results of the exercise in insomnia were reported in
| 1st author (year) | Intervention | Control | PSQI | Secondary outcomes |
|-------------------|--------------|---------|------|--------------------|
|                  |              |         | ISI  | AIS    | SOL | TST | WASO | NOA | SE  |
| SR and MA        |              |         |      |        |     |     |      |     |     |
| Cao (2009) [25]  | Acupressure  | Western medication | P  | P     | P   | P   | P    |     |     |
| Cheuk (2012) [26] | G1: Acupuncture alone | G1: NT | P | P | P | P | P | P | P |
|                  | G2: Acupuncture alone | G2: Placebo or sham treatment | P | P | P | P | P | P | P |
|                  | G3: Acupuncture adjunctive to other treatment | G3: Other treatment alone | P | P | P | P | P | P | P |
|                  | G4: Acupuncture adjunctive to other treatment | G4: Placebo or sham treatment adjunctive to other treatment | P | P | P | P | P | P | P |
| Yeung (2012) [27] | Acupressure | Sham acupressure | P | P |     |     |     |     |     |
| Lan (2015) [28]  | G1: Auricular acupuncture | G1: Sham or placebo | P | P | P | P | P | P | P |
|                  | G2: Auricular acupuncture | G2: Medications comparison | P | P | P | P | P | P | P |
| Lee (2016) [30]  | Acupressure | Drugs, Sham AT | P | P | P |     |     |     |     |
| Shengis (2016) [31] | Acupuncture | Sham/placebo, standard pharmacotherapy | P | N |     |     |     |     |     |
| Choi (2017) [21] | G1: Acupuncture | G1: Sham Acupuncture | P | | | | | | |
|                  | G2: Acupuncture | G2: Conventional drug | | | | | | | |
|                  | G3: Acupuncture | G3: Hormone therapy | | | | | | | |
| Dong (2017) [24] | G1: Acupuncture | G1: Western medicine | pP | | | | | | |
|                  | G2: Acupuncture combined with western medicine | G2: Single medicine | | | | | | | |
|                  | G3: Electroacupuncture | G3: Sham or placebo acupuncture | | | | | | | |
| Huang (2017) [16] | G1: Acupuncture and/or moxibustion | G1: Common therapies (western drugs, sham acupuncture, oral Chinese medicine) | P | | | | | | |
|                  | G2: Acupuncture and/or moxibustion combined with western medication or oral Chinese medicine | G2: Same western medication or oral Chinese medicine | | | | | | | |
| Cao (2019) [33]  | Acupuncture | NT, sham acupuncture, conventional therapy, western medication | P | P | P | | | | |
| Liu (2019) [20]  | Acupuncture | Sham acupuncture or conventional drugs | P | | | | | | |
| Zhao (2019) [18] | G1: APT | G1: Western medications | P | | | | | | |
|                  | G2: APT | G2: Sham APT and NT | | | | | | | |
| Kim (2019) [17]  | Acupressure | Medications | P | | | | | | |
| Liu (2020) [38]  | Acupuncture | Sham acupuncture | P | P | N | N | N | P | P |
| Zhang (2020) [41] | Acupuncture | Sham/placebo acupuncture or WL | P | P | N | P | P | P | P |
| Zhao (2020) [22] | Auricular acupressure | Any type of control group (including conventional western medicine, routine nursing, or blank control) | P | | | | | | |
### Table 3. Continued

| 1st author (year) | Intervention | Control | PSQI | Secondary outcomes |
|-------------------|--------------|---------|------|--------------------|
|                    |              |         | ISI  | AIS    | SOL | TST | WASO | NOA | SE  |
| Mind and body practices |
| Rubio-Arias (2017) [32] | Exercise | Non-exercising controls | P | P |
| Feng (2019) [19] | Tui Na | Estazolam | pP |  |
| Wang (2019) [34] | Meditation, tai chi, qigong, and yoga, alone or in combination | Inactive (TAU or WL) and active (pharmacotherapy and CBT) control | P | P | U | P | N | U | U |
| Wang (2020) [40] | Mindfulness-based interventions | NT, WL, pharmacotherapy, SHE | P | P | N |  |
| Natural products |
| Ni (2015) [29] | CHM, CHM combined with conventional therapies | Placebo, BZDs, non-BZDs, psychotherapy such as CBT and SHE | P | U | P | P |  |
| Zhang (2019) [35] | Chinese herbal medicine (CHM) | Placebo | P | P | P | P | P |
| Birling (2020) [36] | Zao Ren An Shen (ZRAS) | Conventional treatments, a placebo or no-treatment | pP | U | P |  |
| Li (2020) [37] | TCM Yangxin Anshen Therapy (TYAT) | Placebo, BDZs | P | P | N | P |  |
| Wang (2020) [39] | Chaihu Longgu Muli decoction (CLMD) monotherapy or CLMD plus conventional treatment | Placebo, NT, or conventional medicine | P | P |  |
| **SR** |
| Yeung (2009) [42] | Traditional needle acupuncture (TNA) | Placebo, western medication, non-treated controls | P | P | P |  |
| Sarris (2011) [43] | Acupuncture, acupressure | Sham, western medicine | pP | U |  |
| Wang (2017) [44] | HT7 stimulation | No HT7 stimulation, sham | P | P |  |
| Mind and body practices |
| Lowe (2019) [45] | Tai chi, exercise | A suitable, non-physically active control condition (i.e., non-/other intervention, WL) | pP | P | P | U | U | U | U |
| Natural products |
| Sarris (2011) [43] | Tryptophan, Valerian, Kava | Placebo, diphenhydramine (active control) | U | U | U | U | U |  |
| Xie (2013) [23] | Suanzaoren decoction (SZRD) as a monotherapy or as an adjunct therapy to conventional medicine | Conventional medicine (BDZ), placebo, or NT | P |  |

Abbreviations: MA, meta-analysis; SR, systematic review; P, positive result; pP, partially positive result; N, negative result; U, uncertain result; PSQI, Pittsburgh Sleep Quality Index; ISI, Insomnia Severity Index; AIS, Athens Insomnia Scale; APT, auricular plaster therapy; SOL, sleep onset latency; TST, total sleep time; WASO, wake after sleep onset; NOA, number of awakenings; SE, sleep efficiency; CBT, cognitive behavioral therapy; CHM, Chinese herbal medicine; EC, education control; C, control group; NR, non-reported; NT, no treatment; RCT, randomized controlled trial; SHE, sleep hygiene education; TAU, treatment as usual; WL, wait list control.
two SRs/MAs [32, 45]. One SR/MA [32] reported that exercise (aerobic activity and yoga) was more effective than the non-exercising control conditions, and one SR/MA [45] reported improvement but no significance.

3) Tai chi

The PSQI results of tai chi in insomnia were reported in two SRs/MAs [34, 45]. One SR/MA [45] reported that tai chi improved sleep compared to health education, weekly health talk, and sleep seminar. Another SR/MA [34] reported that MBTs, such as meditation, tai chi, qigong, and yoga, can improve sleep quality.

4) Mindfulness-based interventions (MBI)

MBI for insomnia was reported to be more effective in improving sleep than regular health education, pharmacotherapy, and waitlist [40].

3) Natural products

Six out of 30 SRs/MAs [23, 29, 35-37, 39] reported the results of natural products on PSQI for insomnia. Chinese herbal medicine (CHM) was compared with placebo or medication in all six cases. Four SRs/MAs [23, 29, 35, 39] reported that CHM was more effective in treating insomnia, and two SRs/MAs [36, 37] reported that CHM was more effective than a placebo. Still, there was no significant difference with western medicine, but they had fewer side effects.

2) Secondary outcomes

(1) ISI

Nine SRs/MAs (6MAs and 3SRs) [26, 30, 32, 34, 38, 41-43, 45] reported ISI results for insomnia, and eight SRs/MAs (88.9%) reported positive results, and one SR/MA reported an uncertain result [43]. The results of the other secondary outcomes can be found in Table 3.

6. Safety of the included SRs/MAs

Twenty out of 30 SRs/MAs (66.7%) [16-21, 23-29, 31, 33, 36, 37, 39, 41, 42] reported whether they had adverse events. According to the intervention, 14 SRs/MAs (68%, 14/19) reported the side effects of acupuncture, one (20%, 1/5) for MBP, and five for natural products (83.3%, 5/6) (Supplementary Table S8). The side effects included pain, headache, and dizziness, but no SRs/MAs reported serious side effects (Supplementary Table S8).

DISCUSSION

This overview reviewed SRs with or without MA of RCTs for complementary therapies in patients with insomnia published until November 2020. Recently, the overview of complementary and alternative therapies for insomnia was mostly reported based on the RCT, SR, or MA for some CAM interventions [9-11, 46]. On the contrary, there are few overview studies based on MA and SR on the overall CAM for insomnia. Hence, this overview may provide insight into complementary therapies’ MA and SR trends for insomnia.

The publication trend of the SRs/MAs included has appeared since 2009, with more than 50% (51.6%) published in 2019 and 2020. This suggests that SRs/MAs on complementary therapies for improving insomnia have rapidly increased in recent years.

This overview showed that complementary therapies, such as acupuncture, MBP, and natural product intervention, could improve sleep quality. The primary outcome, the PSQI, reported positive and positive results in all interventions. The PSQI is a commonly used tool for assessing the validity of other sleep quality measurement tools [47].

The most frequently reported interventions were acupuncture, followed by natural products. Acupuncture showed a superior result than conventional medications, sham/placebo, and no treatment. This is similar to the results of previous studies [48]. Acupuncture has been studied because it is a representative CAM intervention consistent with studies on other diseases [49-51]. MBPs such as exercise, tai chi, and MBI improved insomnia symptoms and sleep quality for patients with insomnia [32, 34, 40]. Tui Na therapy appeared to be superior to estazolam therapy in treating specific areas (head or abdomen); however, there was no significance in treating combined areas (head and trunk; head, trunk, and extremities) [19]. CHM for insomnia was more effective than a placebo or conventional medications (66.7%, 4/6).

Sleep problems might have a bidirectional relationship with various diseases, such as cancer and mental disorders. Twelve of the 30 SRs/MAs analyzed in this overview reported single or multiple comorbidities, including cancer, depression, and chronic pain [18, 20-22, 24-26, 30, 32, 36, 38, 44]. Therefore, the publication trends reflect the actual clinical situation.

The many studies on insomnia are the most common sleep disorder that can cause interpersonal, social, and occupational problems, increasing steadily every year [1, 4-6].

Decreased concentration and attention in insomnia may be
associated with higher accident rates. Persistent insomnia is also associated with hypertension, major depressive disorders, myocardial infarction, reduced productivity, increased absenteeism at work, and increased economic burden [1]. The results of this overview confirmed the positive effects of acupuncture, MBP, and natural products as measured by PSQI on insomnia. CAM for insomnia is considered a therapy that can be applied safely to insomnia because it has excellent effects, and no severe side effects have been reported.

When interpreting the finding, it is necessary to consider that AMSTAR-2 released in 2017, is more stringent than previous versions. Half of the included SRs/MAs were conducted before the development of AMSTAR-2, with rigorous retrospective assessments applied, resulting in low or critically low ratings. Therefore, to meet the stricter reporting standards in the future, it is necessary to register the protocol before the SR/MA and report the list of excluded studies and funding sources.

This overview had some limitations. First, this overview analyzed only SR with or without MA for RCT to compare the outcomes. The value of observational studies reflecting real-world clinical data has been re-evaluated recently, so analyses including various study designs are necessary for further research [52]. Second, the methodological quality of the included SRs with or without MA for RCT was low, so future reports based on SR/MA with better reporting quality are required. Third, this overview has a limitation in restricting the publishing languages to English and Korean. On the contrary, recent scholarly publications are written mainly in English. Moreover, a significant bias due to language restrictions is not expected as half of the SRs/MAs included in this overview were published by Chinese-affiliated researchers.

CONCLUSION

This overview provides evidence that complementary therapy can improve insomnia symptoms and sleep quality and provide relevant healthcare professionals and patients with a basis for decision-making on the efficacy and safety of complementary therapies for insomnia. PSQI was used to confirm the positive effects of acupuncture, MBP, and natural products on insomnia. More well-designed primary and secondary research will be needed to improve and reinforce the level of evidence for complementary therapies for insomnia disorders under rigorous reporting tools, such as AMSTAR 2.

SUPPLEMENTARY MATERIALS

Supplementary data is available at https://doi.org/10.3831/KPI.2022.25.3.186.

Supplementary Table S1. Search strategies (November 2020).
Supplementary Table S2. List of excluded studies and reasons for exclusion.
Supplementary Table S3. Number of SRs/MAs according to the year and country.
Supplementary Table S4. Interventions of the included SRs/MAs according to the year.
Supplementary Table S5. Methodological and reporting quality of the included SRs/MAs.
Supplementary Table S6. PSQI in MA.
Supplementary Table S7. PSQI in SR.
Supplementary Table S8. Adverse events of the included SRs/MAs.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

AUTHORS’ CONTRIBUTIONS

Conceptualization, Hyun, Yeo, and Lee.; performed the analysis, Yeo, Lee, and Kim; writing—original draft preparation, Yeo, and Hyun; writing—review and editing, Yeo, and Hyun; supervision, Hyun; project administration, Hyun; funding acquisition, Hyun. All authors have read and agreed to the published version of the manuscript.

FUNDING

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, the Republic of Korea (No. HF20C0104).

ORCID

Jin Ju Yeo, https://orcid.org/0000-0002-2146-1215
Jang Won Lee, https://orcid.org/0000-0001-9208-1829
Kyung Sik Kim, https://orcid.org/0000-0001-8648-1420
Min Kyung Hyun, https://orcid.org/0000-0003-0212-8633

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington: Ameri-
can Psychiatric Association; 2013. 947 p.

2. Grandner MA. Sleep, health, and society. Sleep Med Clin. 2020;15(2):319-40.

3. Chokroverty S. Overview of sleep & sleep disorders. Indian J Med Res. 2010;131(2):126-40.

4. Chung S, Cho SW, Jo MW, Yoon S, Lee J, Sim CS. The prevalence and incidence of insomnia in Korea during 2005 to 2013. Psychiatry Investig. 2020;17(6):533-40.

5. Albrecht JS, Wickwire EM, Vadlamani A, Scharf SM, Tom SE. Trends in insomnia diagnosis and treatment among Medicare beneficiaries, 2006-2013. Am J Geriatr Psychiatry. 2019;27(3):301-9.

6. Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Med. 2014;15(2):173-9.

7. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 national health interview survey data. Arch Intern Med. 2006;166(16):1775-82.

8. Bertisch SM, Wells RE, Smith MT, McCarthy EP. Use of relaxation techniques and complementary and alternative medicine by American adults with insomnia symptoms: results from a national survey. J Clin Sleep Med. 2012;8(6):681-91.

9. Cheng B, Liu Y, Tian J, Gao R, Liu Y. Complementary and alternative medicine for the treatment of insomnia: an overview of scientific evidence from 2008 to 2018. Curr Vasc Pharmacol. 2020;18(4):307-21.

10. Huang J, Wu M, Liang S, Qin X, Shen M, Li J, et al. A critical overview of systematic reviews and meta-analyses on acupuncture for poststroke insomnia. Evid Based Complement Alternat Med. 2020;2020:2032575.

11. He W, Li M, Zuo L, Wang M, Jiang L, Shan H, et al. Acupuncture for treatment of insomnia: an overview of systematic reviews. Complement Ther Med. 2019;42:407-16.

12. Buyssse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.

13. Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-8.

14. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555-60.

15. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

16. Huang KY, Liang S, Grellet A, Zhang JB. Acupuncture and moxibustion for primary insomnia: a systematic review and meta-analysis of randomized controlled trials. Eur J Integr Med. 2017;12:93-107.

17. Kim SH, Jeong JH, Lim JH, Kim BK. Acupuncture using pattern-identification for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials. Integr Med Res. 2019;8(3):216-26.

18. Zhao H, Li D, Yang Y, Liu Y, Li J, Mao J. Auricular plaster therapy for comorbid insomnia: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2019;2019:7120169.

19. Feng G, Han M, Li X, Geng L, Miao Y. Clinical effectiveness of Tui Na for insomnia compared with estazolam: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2019;47:102186.

20. Liu F, You J, Li Q, Fang T, Chen M, Tang N, et al. Acupuncture for chronic pain-related insomnia: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:5381028.

21. Choi TY, Kim JJ, Lim HJ, Lee MS. Acupuncture for managing cancer-related insomnia: a systematic review of randomized clinical trials. Integr Cancer Ther. 2017;16(2):135-46.

22. Zhao ZH, Zhou Y, Li WH, Tang ZH, Xia TW, Han L. Auricular acupressure in patients with hypertension and insomnia: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2020;2020:7279486.

23. Xie CL, Gu Y, Wang WW, Lu L, Fu DL, Liu AJ, et al. Efficacy and safety of Suanzaoren decoction for primary insomnia: a systematic review of randomized controlled trials. BMC Complement Altern Med. 2013;13:18.

24. Dong B, Chen Z, Yin X, Li D, Ma J, Yin P, et al. The efficacy of acupuncture for treating depression-related insomnia compared with a control group: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:9614810.

25. Cao H, Pan X, Li H, Liu J. Acupuncture for treatment of insomnia: a systematic review of randomized controlled trials. J Altern Complement Med. 2009;15(11):1171-86.

26. Cheuk DK, Yeung WF, Chung KF, Wong V. Acupuncture for insomnia. Cochrane Database Syst Rev. 2012;(9):CD005472.

27. Yeung WF, Chung KF, Poon MM, Ho FY, Zhang SP, Zhang ZJ, et al. Acupressure, reflexology, and auricular acupuncture for insomnia: a systematic review of randomized controlled trials. Sleep Med. 2012;13(8):971-84.

28. Lan Y, Wu X, Tan HJ, Wu N, Xing JJ, Wu FS, et al. Auricular acupuncture with seed or pellet attachments for primary insomnia: a systematic review and meta-analysis. BMC Complement Altern Med. 2015;15:103.
29. Ni X, Shergis JL, Guo X, Zhang AL, Li Y, Lu C, et al. Updated clinical evidence of Chinese herbal medicine for insomnia: a systematic review and meta-analysis of randomized controlled trials. Sleep Med. 2015;16(12):1462-81.

30. Lee SH, Lim SM. Acupuncture for insomnia after stroke: a systematic review and meta-analysis. BMC Complement Altern Med. 2016;16:228.

31. Shergis JL, Ni X, Jackson ML, Zhang AL, Guo X, Li Y, et al. A systematic review of acupuncture for sleep quality in people with insomnia. Complement Ther Med. 2016;26:11-20.

32. Rubio-Arias JÁ, Marín-Cascales E, Ramos-Campo DJ, Hernández AV, Pérez-López FR. Effect of exercise on sleep quality and insomnia in middle-aged women: a systematic review and meta-analysis of randomized controlled trials. Maturitas. 2017;100:49-56.

33. Cao HJ, Yu ML, Wang LQ, Fei YT, Xu H, Liu JP. Acupuncture for primary insomnia: an updated systematic review of randomized controlled trials. J Altern Complement Med. 2019;25(5):451-74.

34. Wang X, Li P, Pan C, Dai L, Wu Y, Deng Y. The effect of mind-body therapies on insomnia: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:9359807.

35. Zhang H, Liu P, Wu X, Zhang Y, Cong D. Effectiveness of Chinese herbal medicine for patients with primary insomnia: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019;98(24):e15967.

36. Birling Y, Jia M, Li G, Sarris J, Bensoussan A, Zhu X. Zao Ren An Shen for insomnia: a systematic review with meta-analysis. Sleep Med. 2020;69:41-50.

37. Li F, Xu B, Shi H, Zhang T, Song Z, Chen Y, et al. Efficacy and safety of TCM Yangxin Anshen Therapy for insomnia: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(8):e19330.

38. Liu C, Xi H, Wu W, Wang X, Qin S, Zhao Y, et al. Placebo effect of acupuncture on insomnia: a systematic review and meta-analysis. Ann Palliat Med. 2020;9(1):19-29.

39. Wang X, Ju J, Li J, Fan Y, Xu H. Chaihu Longgu Muli decoction, a Chinese herbal formula, for the treatment of insomnia: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(40):e22462.

40. Wang YY, Wang F, Zheng W, Zhang L, Ng CH, Ungvari GS, et al. Mindfulness-based interventions for insomnia: a meta-analysis of randomized controlled trials. Behav Sleep Med. 2020;18(1):1-9.

41. Zhang J, He Y, Huang X, Liu Y, Yu H. The effects of acupuncture versus sham/placebo acupuncture for insomnia: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2020;41:101253.

42. Yeung WF, Chung KE, Leung YK, Zhang SP, Law AC. Traditional needle acupuncture treatment for insomnia: a systematic review of randomized controlled trials. Sleep Med. 2009;10(7):694-704.

43. Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Sleep Med Rev. 2011;15(2):99-106.

44. Wang Z, Hu X, Su J, Gao X, Xu N, Xing Y, et al. The efficacy and safety stimulating a single acu-point shenmen (HT 7) for managing insomnia: a systematic review of randomized controlled trials. Eur J Integr Med. 2017;15:17-22.

45. Lowe H, Haddock G, Mulligan LD, Gregg L, Fuzellier-Hart A, Carter LA, et al. Does exercise improve sleep for adults with insomnia? A systematic review with quality appraisal. Clin Psychol Rev. 2019;68:1-12.

46. Huang J, Shen M, Qin X, Huang Y. Effectiveness of auricular acupuncture for insomnia: an overview of systematic reviews. Evid Based Complement Alternat Med. 2020;2020:6920902.

47. Spielmanns M, Bost D, Windisch W, Alter P, Greulich T, Nell C, et al. Measuring sleep quality and efficiency with an activity monitoring device in comparison to polysomnography. J Clin Med Res. 2019;11(12):825-33.

48. Zhao FY, Fu QQ, Kennedy GA, Conduit R, Zhang WJ, Wu WZ, et al. Can acupuncture improve objective sleep indices in patients with primary insomnia? A systematic review and meta-analysis. Sleep Med. 2021;80:244-59.

49. Lee SM, Choi HC, Hyun MK. An overview of systematic reviews: complementary therapies for cancer patients. Integr Cancer Ther. 2019;18:1534735419890029.

50. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.

51. National Heart, Lung, and Blood Institute. Insomnia [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute; 2020 [cited 2021 Nov 7]. Available from: https://www.nhlbi.nih.gov/health/insomnia.

52. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763-74.